A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH)

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 10, Issue 4, 2000, Pages 195-203

  MacMahon, M ^a   Kirkpatrick, C ^a   Cummings, C E ^b   Clayton, A ^b   Robinson, P J ^b   Tomiak, R H H ^b   Liu, M ^c   Kush, D ^c   Tobert, J ^c  

^a Chiltern International   (United Kingdom)

^b Merck Sharp & Dohme Limited   (United Kingdom)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

C reactive protein; Cholesterol; Coronary heart disease; Folic acid; Homocysteine; Simvastatin

Indexed keywords

CHOLESTEROL; CYANOCOBALAMIN; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; FACTORIAL ANALYSIS; FEMALE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MULTICENTER STUDY; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL;

CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FACTOR ANALYSIS, STATISTICAL; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PILOT PROJECTS; PLACEBOS; SIMVASTATIN; TRIGLYCERIDES; VITAMIN B 12;

EID: 0034252616     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D (1986) Serum cholesterol, blood pressure and mortality: implications from a cohort of 361,662 men. Lancet 2: 933-936
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D for the Multiple Risk Factor Intervention Trial Research Group (1993) Diabetes, other risk factors and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16: 434-444
3. Jacobs D, Blackburn H, Higgins M Reed D, Iso H, McMillan G, Neaton J, Nelson J, Potter J, Rifkind B, Rossouw J, Shekelle R, Yusuf S, for Participants in the Conference on Low Cholesterol: Mortality Association (1992) Report of the conference on low blood cholesterol: mortality associations. Circulation 86: 1046-1060
4. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389
5. Chen Z, Peto R, Collins R, MacMahoh S, Lu J, Li W (1991) Serum cholesterol concentration and coronary heart disease in population with low-cholesterol concentrations. Br Med J 303: 276-282
6. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD (1995) Cholesterol reduction yields clinical benefit. A new look at old data. Circulation 91: 2274-2282
7. Danesh J, Lewington S (1998) Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk 5: 229-232
8. Homocysteine Lowering Trialists' Collaboration (1998) Blood homocysteine lowering with folic acid based supplements: A systematic overview of the randomised trials. BMJ 316: 894-898
9. Myers GL, Cooper GR, Winn CL, Smith SJ (1989) The Centers for Disease Control - National Heart, Lung and Blood Institute Lipid Standardization Program: an approach to accurate and precise lipid measurements. Clin Lab Med 9: 105-135
10. Steiner PM, Friedel J, Bremner WF, Stein EA (1981) Standardization of micro-methods for plasma cholesterol, triglyceride and HDL-cholesterol with the lipid Research clinics' methodology. J Clin Chem 19: 850
11. Warnick GR, Albers JJ (1978) A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high-density lipoprotein cholesterol. J Lipid Res 19: 65-76
12. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274: 1049-1057
13. Mayer EL, Jacobson DW, Robinson K (1996) Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 27: 517-527
14. Graham IM, Daly LE, Refsum HM, Robinson K, Brattstrom LE, Ueland PM, Palma-Reis RJ, Boers GHJ, Sheahan RG, Israelsson B, Uiterwaal CS, Meleady R, McMaster D, Verhoef P, Witteman J, Rubba P, Bellet H, Wautrecht JC, de Valk HW, Sales Luis AC, Parrot-Rouland FM, Tan KS, Higgins I, Garcon D, Medrano MJ, Candito M, Evans AE, Andria G (1997) Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA 277: 1775-1781
15. McCully KS (1969) Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 56: 111-128
16. Domagala TB, Undas A, Libura M, Szczeklik A (1998) Pathogenesis of vascular disease in hyperhomocysteinaemia. J Cardiovasc Risk 5: 239-247
17. Ernst E, Resch KL (1993) Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 118: 956-963
18. Mitropoulos KA, Armitage JM, Collins R, Meade TW, Reeves BE, Wallendszus KR, Wilson SS, Lawson A, Peto R (1997) Randomised placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. Eur Heart J 18: 235-241
19. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A (1994) The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 331: 417-424
20. Ridker PM, Glynn RJ, Hennekens CH (1998) C-reactive protein adds to the predictive value of total and HDL-C in determining risk of first myocardial infarction. Circulation 97: 2007-2011
21. Danesh J, Collins R, Appleby P, Peto R (1998) Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 279: 1477-1482
22. Strandberg TE, Vanhanen H, Tikkanen MJ (1999) Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet (Letter) 353 (9147): 118-119
23. Kluft C, de Maat MPM, Gevers L, Leuven JA, Potter van Loon BJ, Mohrschlandt MF (1999) Statins and C-reactive protein. Lancet (Letter) 353 (9160): 1274
24. Endres M, Laufs U, Huang Z Nakamura T, Huang P, Moskovitz MA, Liao JK (1998) Stroke protection by a 3-hydroxy-3-methyl-glutaryl (HMG)-CoA reductase inhibitor mediated by endothelial nitric oxide synthase (Cerebral blood flow/cerebral ischemia). Proc Natl Acad Sci 95: 8880-8885
25. Wenke K, Meiser B, Thiery J Neagel D, von Scheidt W, Steibeck G, Seidel D, Reichart B (1997) Simvastatin reduces graft vessel disease and mortality after heart transplantation (A four year Randomised Trial). Circulation 96: 1398-1402
26. Davidson MH, Stein EA, Dujovne CA Hunninghake DB, Weiss SR, Knopp RH, Illingworth DR, Mitchel YB, Melino MR, Zupkis RV, Dobrinska MR, Amin RD, Tobert JA (1997) The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol 79: 38-42
27. Stein EA, Davidson MH, Dobs AS Schrott H, Dujovne CA, Bays H, Weiss SR, Melino MR, Stepanavage ME, Mitchel YB, (1998) Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. Am J Cardiol 82: 311-316
28. Ose L, Kastelein, JJP Scott R Stein EA, Campodonico S, Escobar JD, Tate AC, Corsetti L, Shahane A, Mitchel YB, Mercuri M (1998) Efficacy and six-month safety of simvastatin 80 mg/day: Results from the Worldwide Simvastatin Expanded Dose Program (WSEDP). Nutr Metab Cardiovasc Dis 8: 143-151
29. Pedersen TR, Faergeman, O (1999) Simvastatin seems unlikely to cause impotence. Br Med J (Letter) 318: 192